Inhalation Sciences to Present abstracts from the FDA-Funded Evaluation Study on DissolvIt® and the APRINHA Project at the 2025 DDL Conference
Inhalation Sciences AB (ISAB) today announced that both of its submitted abstracts have been accepted for presentation at the upcoming Drug Delivery to the Lungs (DDL) Conference in December. ISAB’s Chief Scientific Officer and founder, Assoc. Professor. Per Gerde and Director of Projects, PhD Maria Malmlöf, will present results from two major research initiatives, highlighting the company’s latest advances in inhalation drug development.
This recognition underscores ISAB’s continued leadership in advancing cutting-edge research within inhaled drug development.
Assoc. Professor. Per Gerde, will have a podium presentation on the pharmacokinetic (PK) studies from the European research project "New Inhalation Formulations for Improved Delivery of Antimicrobials" (APRINHA). The APRINHA project is developing and evaluating five innovative formulations of the antibiotic apramycin, aiming to create an effective inhaled antibiotic treatment for lower respiratory tract infections (LRTIs), including those caused by antibiotic-resistant bacteria. ISAB was selected to conduct the pharmacokinetic studies in the APRINHA project due to the unique precision and capabilities of its proprietary PreciseInhale® platform technology.The APRINHA project is coordinated by the University of Zurich and brings together leading academic and industry partners across Europe.
Furthermore, PhD Maria Malmlöf will present the results from the FDA-funded evaluation study of ISAB’s in vitro dissolution module, DissolvIt®. This study demonstrates that DissolvIt® generates pharmacokinetic (PK) data capable of predicting clinical plasma profiles, supporting its use in bioequivalence assessments.
In addition to the DDL conference, Inhalation Sciences will also be exhibiting at the upcoming MVIC inhalation symposium in Lund on October 8-9, where company representatives will be available at their booth to discuss these studies and broader research into advanced pulmonary drug delivery technologies.
For more information, please contact:
Manoush Masarrat, CEO
Phone: +46 (0) 73 628 9153
E-mail: manoush.masarrat@inhalation.se
About Inhalation Sciences Sweden AB (publ)
Inhalation Sciences is a cutting-edge Contract Research Organization (CRO) specializing in inhalation drug development. Leveraging our proprietary technology platform, PreciseInhale®, we empower our clients to de-risk and accelerate their R&D pipelines by delivering high-resolution, predictive data early in the development process.
